Jane S. Ricciuti, RPh, MS


September 20, 2002

In This Article

Cardiovascular Agents

(treprostinil sodium) Injection

Manufacturer: United Therapeutics

Drug Approval Classification: Original New Drug Application (Approval Date: 5/21/02)

Indication: Remodulin is indicated as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with New York Heart Association (NYHA) Class II-IV symptoms to diminish symptoms associated with exercise.

Dosing: Remodulin is administered by continuous subcutaneous infusion. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated, the infusion rate should be reduced to 0.625 ng/kg/min. The infusion rate should be increased in increments of no more than 1.25 ng/kg/min per week for the first 4 weeks and then no more than 2.5 ng/kg/min per week for the remaining duration of infusion, depending on clinical response. There is little experience with doses > 40 ng/kg/min. Abrupt cessation of infusion should be avoided.

Clinical Summary: Two pivotal trials that were submitted with Remodulin's New Drug Application were 12-week international multicenter, double-blind, randomized, parallel placebo-controlled comparisons of the safety and efficacy of subcutaneous treprostinil sodium plus conventional therapy to conventional therapy in patients with pulmonary hypertension. In both trials, a total of 470 patients with pulmonary hypertension of diverse etiology were randomized.

The change in 6-minute walking distance was the primary end point to demonstrate exercise capacity. The median change from baseline was 10 meters for Remodulin-treated patients vs 0 meters for the placebo group. Other end points demonstrated improvement in dyspnea score, fatigue, and signs and symptoms of pulmonary hypertension.

Adverse Effects: Adverse effects reported with Remodulin included infusion- site pain (85%) and infusion-site reaction (83%). Other, less common adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%), and hypotension (4%).

Pharmacokinetics: There are 3 relevant pharmacodynamic effects for Remodulin:

Inhibition of platelet activation,

  • Vasorelaxation, and

  • Inhibition of smooth muscle cell proliferation.

  • Remodulin is metabolized in the liver with < 4% excreted unchanged in the urine. Five metabolites (of unknown activity) are formed. The metabolic pathways used have not been identified. Remodulin is rapidly cleared, with a half-life of 2-4 hours. The primary route of elimination is urine (79%). There appears to be no significant inhibition of P450 isozymes. Hepatic impairment significantly increased both the Cmax and the AUC.

    Remodulin (treprostinil) Labeling


    Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.